Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2015 1
2016 2
2017 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS, Sinha MS, Avorn J. Kesselheim AS, et al. JAMA Intern Med. 2017 Nov 1;177(11):1658-1664. doi: 10.1001/jamainternmed.2017.4329. JAMA Intern Med. 2017. PMID: 28892528 Review.
The high prices of brand-name prescription drugs are a growing source of controversy in the United States. Manufacturers of brand-name drugs can command high prices because they are protected from generic competition by two types of government-g …
The high prices of brand-name prescription drugs are a growing source of controversy in the United States. Manuf …
The unintended effects of the Medicare Part D low income subsidy.
Decarolis F. Decarolis F. Health Policy. 2015 May;119(5):597-603. doi: 10.1016/j.healthpol.2015.01.008. Epub 2015 Feb 10. Health Policy. 2015. PMID: 25716285
OBJECTIVES: Medicare Part D is the voluntary program that provides insurance for prescription drugs to 37 million US elderly. This form of public insurance is delivered exclusively through a choice-based private insurance market, where Medicare pays va …
OBJECTIVES: Medicare Part D is the voluntary program that provides insurance for prescription drugs to 37 million US elderly. …
Updated trends in US brand-name and generic drug competition.
Grabowski H, Long G, Mortimer R, Boyo A. Grabowski H, et al. J Med Econ. 2016 Sep;19(9):836-44. doi: 10.1080/13696998.2016.1176578. Epub 2016 Apr 20. J Med Econ. 2016. PMID: 27064194
OBJECTIVE: To provide updated evidence on US trends in: market exclusivity periods (MEPs, time between brand-name drug launch and first generic competitors) for new molecular entities (NMEs); likelihood, timing and number of Hatch-Waxman Act Paragraph IV patent chal …
OBJECTIVE: To provide updated evidence on US trends in: market exclusivity periods (MEPs, time between brand-name drug launch …
Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J, Seeger JD, Donneyong M, Gagne JJ, Avorn J, Kesselheim AS. Luo J, et al. JAMA Intern Med. 2016 Sep 1;176(9):1317-23. doi: 10.1001/jamainternmed.2016.3384. JAMA Intern Med. 2016. PMID: 27367749
IMPORTANCE: In November 2011, the cholesterol level-lowering medication atorvastatin calcium became available in the United States as a generic drug. However, only a single generic form (from a manufacturer that qualified for market exclusivity by chal …
IMPORTANCE: In November 2011, the cholesterol level-lowering medication atorvastatin calcium became available in the United States
Diverted medications and new psychoactive substances-A chemical network analysis of discarded injecting paraphernalia in Hungary.
Gyarmathy VA, Péterfi A, Figeczki T, Kiss J, Medgyesi-Frank K, Posta J, Csorba J. Gyarmathy VA, et al. Int J Drug Policy. 2017 Aug;46:61-65. doi: 10.1016/j.drugpo.2017.05.003. Epub 2017 Jun 17. Int J Drug Policy. 2017. PMID: 28628897
BACKGROUND: Until about 2010, people who inject drugs (PWIDs) injected almost exclusively heroin and amphetamines in Hungary. After 2010, self-reported studies have indicated a dominance of new psychoactive substances on the drug market for injectable drug
BACKGROUND: Until about 2010, people who inject drugs (PWIDs) injected almost exclusively heroin and amphetamines in Hungary. …
The US orphan drug programme 1983-1995.
Shulman SR, Manocchia M. Shulman SR, et al. Pharmacoeconomics. 1997 Sep;12(3):312-26. doi: 10.2165/00019053-199712030-00004. Pharmacoeconomics. 1997. PMID: 10170457 Review.
In light of a recent challenge to the Food and Drug Administration's (FDA's) authority under the Act, we also examine the interplay between the exclusivity provision of the Act and the orphan drug regulations that define when 2 drugs will be considered …
In light of a recent challenge to the Food and Drug Administration's (FDA's) authority under the Act, we also examine the inte …
Direct-to-consumer prescription drug advertising, 1989-1998. A content analysis of conditions, targets, inducements, and appeals.
Bell RA, Kravitz RL, Wilkes MS. Bell RA, et al. J Fam Pract. 2000 Apr;49(4):329-35. J Fam Pract. 2000. PMID: 10778839
BACKGROUND: We conducted a content analysis of consumer-targeted prescription drug advertisements to explore trends in prevalence, shifts in the medical conditions for which drugs are promoted, reliance on financial and nonmonetary inducements, and appeals us …
BACKGROUND: We conducted a content analysis of consumer-targeted prescription drug advertisements to explore trends in prevale …
Feedback